Exposure of the treated areas to natural or artificial sunlight, including tanning booths, sunlamps, or phototherapy; use should be limited or avoided;
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Children <2 yr (safety and effectiveness not established).
Exact mechanism is unknown, but may affect keratinocyte proliferation and differentiation, and decrease the action of proinflammatory cytokines.
Therapeutic effects:
Decreased severity of plaque psoriasis.
Classifications⬆⬇
Therapeutic Classification: antipsoriatics
Pharmacologic Classification: vitamin d analogues
Pharmacokinetics⬆⬇
Absorption: Although intended action is skin, some systemic absorption follows topical use.
Distribution: Unknown.
Metabolism/Excretion: Absorbed calcitriol undergoes enterohepatic recycling and is excreted in bile.
Half-Life: 58 hr.
Canadian Brand Names⬆⬇
Silkis
Time/Action Profile⬆⬇
ROUTE
ONSET
PEAK
DURATION
Topical
unknown
within 8 wk
unknown
Patient/Family Teaching⬆⬇
Instruct patient to apply calcitriol ointment as directed. Do not use more than 200 g/wk in patients ≥7 yr or 100 g/wk in patient 26 yr of age.
Caution patient to avoid excessive exposure of treated areas to natural or artificial sunlight, including tanning booths and sunlamps; may increase risk of skin tumors.
Advise patient to report any signs of adverse reactions to health care professional.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Advise breastfeeding patient to avoid applying ointment directly to nipple and areola.